We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Merit Medical (MMSI) Completes Cianna Medical Acquisition
Read MoreHide Full Article
Merit Medical Systems, Inc. (MMSI - Free Report) announced that it has completed the acquisition of Cianna Medical, Inc., based in Aliso Viejo, CA.
The deal was announced on Oct 1. Following the announcement, shares of Merit Medical plunged 4.7% to close at $59.10 yesterday. The transaction included an upfront payment of an upfront payment of $135 million along with a $15-million payment for securing supply chain metrics.
However, Merit Medical outperformed its industry in a year's time. The stock has surged almost 44.7%, better than the industry's 1.6% growth and the S&P 500’s 8.2% gain. Analysts believe that this Zacks Rank #2 (Buy) company has been leveraging on bolt-on buyouts to drive inorganic growth.
Cianna Medical is a leading player in breast cancer treatments, especially in wire-free breast localization. Its flagship SCOUT and SAVI Brachy technologies are FDA-cleared and make radiation therapy easy. Per management, the platforms are complementary to Merit Medical’s strategic biopsy initiatives.
Moving ahead, Merit Medical is likely to market Cianna Medical’s SAVI BRACHY, which uses thin tubes to deliver radiation to lumpectomy sites. Further, the company plans to retain the entire commercial and R&D teams of Cianna Medical.
Per Grand View Research, the global breast lesion localization methods market size was worth $507.7 million in 2016 and is estimated to reach $1,577.6 million by 2025, at a CAGR of 13.3%.Considering the solid prospects, we expect Merit Medical to gain traction in the niche space.
Guidance
For 2018, the acquisition will impact Merit Medical’s earnings per share to the extent of 2 cents (on an adjusted basis). Adjusted gross margins are projected to be in the range of 70-75% on the Cianna Medical products. This, in turn, might drive Merit Medical’s adjusted gross margin by 10-20 basis points. This acquisition is also likely to rake in revenues between $5 miilion and $7 million.
For 2019, the proposed transaction will be accretive to Merit Medical’s earnings, which are expected in the range of 8-13 cents per share (on an adjusted basis). Adjusted gross margins are envisioned in the 70-75% band on Cianna Medical products. This, in turn, might drive Merit Medical’s adjusted gross margin by 55-130 basis points. Revenue growth is anticipated to be within $50 million and $56 million.
Key Picks
A few other top-ranked stocks in the broader medical space are Stryker Corporation (SYK - Free Report) , STAAR Surgical Company (STAA - Free Report) and Veeva Systems (VEEV - Free Report) .
Stryker has a long-term expected earnings growth rate of 10% and a Zacks Rank #2.
Veeva Systems’ long-term earnings growth rate is projected at 19.3%. The stock carries a Zacks Rank of 2.
Today's Stocks from Zacks' Hottest Strategies
It's hard to believe, even for us at Zacks. But while the market gained +21.9% in 2017, our top stock-picking screens have returned +115.0%, +109.3%, +104.9%, +98.6%, and +67.1%.
And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - 2017, the composite yearly average gain for these strategies has beaten the market more than 19X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation.
Image: Bigstock
Merit Medical (MMSI) Completes Cianna Medical Acquisition
Merit Medical Systems, Inc. (MMSI - Free Report) announced that it has completed the acquisition of Cianna Medical, Inc., based in Aliso Viejo, CA.
The deal was announced on Oct 1. Following the announcement, shares of Merit Medical plunged 4.7% to close at $59.10 yesterday. The transaction included an upfront payment of an upfront payment of $135 million along with a $15-million payment for securing supply chain metrics.
However, Merit Medical outperformed its industry in a year's time. The stock has surged almost 44.7%, better than the industry's 1.6% growth and the S&P 500’s 8.2% gain. Analysts believe that this Zacks Rank #2 (Buy) company has been leveraging on bolt-on buyouts to drive inorganic growth.
Merit Medical Systems, Inc. Price
Merit Medical Systems, Inc. Price | Merit Medical Systems, Inc. Quote
Significance of the Deal
Cianna Medical is a leading player in breast cancer treatments, especially in wire-free breast localization. Its flagship SCOUT and SAVI Brachy technologies are FDA-cleared and make radiation therapy easy. Per management, the platforms are complementary to Merit Medical’s strategic biopsy initiatives.
Moving ahead, Merit Medical is likely to market Cianna Medical’s SAVI BRACHY, which uses thin tubes to deliver radiation to lumpectomy sites. Further, the company plans to retain the entire commercial and R&D teams of Cianna Medical.
Per Grand View Research, the global breast lesion localization methods market size was worth $507.7 million in 2016 and is estimated to reach $1,577.6 million by 2025, at a CAGR of 13.3%.Considering the solid prospects, we expect Merit Medical to gain traction in the niche space.
Guidance
For 2018, the acquisition will impact Merit Medical’s earnings per share to the extent of 2 cents (on an adjusted basis). Adjusted gross margins are projected to be in the range of 70-75% on the Cianna Medical products. This, in turn, might drive Merit Medical’s adjusted gross margin by 10-20 basis points. This acquisition is also likely to rake in revenues between $5 miilion and $7 million.
For 2019, the proposed transaction will be accretive to Merit Medical’s earnings, which are expected in the range of 8-13 cents per share (on an adjusted basis). Adjusted gross margins are envisioned in the 70-75% band on Cianna Medical products. This, in turn, might drive Merit Medical’s adjusted gross margin by 55-130 basis points. Revenue growth is anticipated to be within $50 million and $56 million.
Key Picks
A few other top-ranked stocks in the broader medical space are Stryker Corporation (SYK - Free Report) , STAAR Surgical Company (STAA - Free Report) and Veeva Systems (VEEV - Free Report) .
Stryker has a long-term expected earnings growth rate of 10% and a Zacks Rank #2.
With a Zacks Rank #1 (Strong Buy), STAAR Surgical’s has an average four-quarter positive earnings surprise of 400%. You can see the complete list of today’s Zacks #1 Rank stocks here.
Veeva Systems’ long-term earnings growth rate is projected at 19.3%. The stock carries a Zacks Rank of 2.
Today's Stocks from Zacks' Hottest Strategies
It's hard to believe, even for us at Zacks. But while the market gained +21.9% in 2017, our top stock-picking screens have returned +115.0%, +109.3%, +104.9%, +98.6%, and +67.1%.
And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - 2017, the composite yearly average gain for these strategies has beaten the market more than 19X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation.
See Them Free>>